EMERYVILLE, Calif. - Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company with a ...

The company’s Heplisav-B vaccine, which is the only two-dose adult Hepatitis B vaccine, reported a significant year-over-year sales increase, reaching the upper end of the guidance for 2024.

Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $ ...

HEPLISAV-B achieved preliminary quarterly net product revenue of $71M for the fourth quarter of 2024, an increase of 39% compared to $51M for the fourth quarter of 2023. Q4 revenue consensus $71.71M.

"We are excited to announce that HEPLISAV-B has achieved record annual revenue in 2024, reflecting 26% growth year-over-year, and positioning us at the upper tier of our updated guidance range.

The study, reported Dec. 1 in JAMA, showed that hepatitis B vaccine with a cytosine phosphoguanine adjuvant, known as HepB-CpG, (trade name Heplisav-B) induced protective levels of antibodies in ...

Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein ...